logo
How Asteroid Mining Could Make the World's First Trillionaire

How Asteroid Mining Could Make the World's First Trillionaire

Yahoo28-04-2025

Astrophysicist Neil deGrasse Tyson has long posited that the world's first trillionaire will emerge from asteroid mining. With advancements in space technology and resource extraction, this prediction is finally gaining traction.​
Asteroids are rich in metals like platinum, nickel, and iron, often in concentrations far exceeding those found on Earth. For instance, some asteroids contain platinum at levels up to 15 parts per million, compared to Earth's 0.0005 parts per million. Some asteroids even contain enough precious metals to make everyone on the planet billionaires.
These metals are crucial for renewable energy technologies and fuel cells, making them highly valuable, which could easily lead to whoever perfects mining them becoming the world's first ever trillionaire.
In an interview with CNBC's 'On The Money' in 2015, Tyson said: "The first trillionaire there will ever be is the person who exploits the natural resources on asteroids.
"There's this vast universe of limitless energy and limitless resources. I look at wars fought over access to resources. That could be a thing of the past, once space becomes our backyard."
As of yet, no individual has managed to reach trillionaire status. The combined wealth of the world's billionaires is substantial, but it falls short of the $1 trillion mark, although many speculate that Elon Musk will become the world's first ever trillionaire by 2027, and Jeff Bezos might not be too far behind him either.
According to Business Insider, a single asteroid could contain around £40 billion worth of platinum, showing the immense wealth potential of asteroid mining.
Recent developments indicate that asteroid mining is becoming more feasible. In February 2025, California-based AstroForge launched its Odin spacecraft on a SpaceX Falcon 9 rocket, targeting asteroid 2022 OB5 to test mining technologies.
While the mission faced communication challenges, it marks a significant step toward commercial asteroid mining.
But how far are we from actually seeing resources from space being mined and brought back to Earth?
Well, billionaire Victor Vescovo, one of the investors in AstroForge told the BBC: "Bring back a few micrograms to show it can be done and then scaling the process up is relatively straightforward.
"To fully realise asteroid mining may be a multi-decade project. But it's just a mathematical problem."
With the vast amounts of money to be made from mining asteroids, could greed do humanity a favour for once, and speed up the race to become the first asteroid miners?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dangote hails Nigeria's emergence as Africa's leading cement exporter
Dangote hails Nigeria's emergence as Africa's leading cement exporter

Business Insider

time28 minutes ago

  • Business Insider

Dangote hails Nigeria's emergence as Africa's leading cement exporter

Africa's richest man, Aliko Dangote, has hailed Nigeria's emergence as the continent's leading cement exporter, crediting strategic investments and local production capacity for transforming the country from a major importer into a dominant player in the African cement market. Aliko Dangote emphasized Nigeria's achievement as Africa's top cement exporter due to local investments and production capacity. Nigeria transitioned from being the world's second-largest cement importer to a dominant exporter in the region. Strategic industry advancements in Nigeria highlight the transformative power of local industrial investments. Dangote noted that Nigeria, once the second-largest importer of cement globally, now exports more cement than any other African country, thanks to massive local investment in production capacity. Aliko Dangote, Africa's richest man and President of the Dangote Group, delivered a compelling address at the recently held Gates Foundation Goalkeepers event in Nigeria, showcasing the country's progress in health and business sectors. Speaking alongside philanthropist Bill Gates, Dangote emphasized the impact of strategic partnerships and domestic investment in reversing long-standing challenges. Shifting to the business sector, Dangote emphasized the transformative role of industrial investments in reversing Nigeria's dependency on imports. 'Nigeria used to be the second-largest importer of cement in the world,' he said. ' Now we export more cement than any other African country.' Dangote's cement export milestone Nigerian-based Dangote Cement is Africa's largest cement producer, boasting a total installed capacity of 48.6 million tonnes per annum (Mt/a) across the continent. Of this, 32.3 Mt/a is installed within Nigeria, while the remaining 16.3 Mt/a capacity is spread across nine other African countries, including Tanzania, South Africa, Ethiopia, Cameroon, Republic of Congo, Ghana, Senegal, Zambia, and Sierra Leone. To reaffirm its status as Africa's largest cement producer, Dangote Cement last year announced the dispatch of seven shipments of clinker from Nigeria to Ghana and Cameroon. The company also reported that clinker exports for the first quarter of 2024 surged by 87.2 percent, reaching 264,000 metric tonnes, marking a significant milestone in Nigeria's transition from a bulk cement importer to a major exporter in the region. Clinker is a solid, granular substance formed by heating limestone and other raw materials in a kiln. It is the intermediate product in cement production and is ground into fine powder and blended with gypsum to produce finished cement. Until recently, Nigeria ranked among the world's largest importers of cement. However, sustained investments in local manufacturing—led by Dangote Cement—have enabled the country to not only meet domestic demand but also expand into regional markets. Sources within the company indicate that clinker exports are set to increase significantly in the coming months as Dangote Cement scales up operations and targets additional African destinations.

$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030

Yahoo

time31 minutes ago

  • Yahoo

$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030

The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

Citigroup to axe around 3,500 tech roles in China
Citigroup to axe around 3,500 tech roles in China

Yahoo

time32 minutes ago

  • Yahoo

Citigroup to axe around 3,500 tech roles in China

Citigroup is trimming its workforce size by approximately 3,500 at two of its technology centres in China, reported Reuters. The aim is to consolidate and streamline the bank's global technology operations to enhance its risk and data management systems. The staffing reductions will affect the China Citi Solution Centres in Shanghai and Dalian, with the bank planning to complete the process by the start of the fourth quarter of this year, the news agency said citing a statement by Citi. The jobs being cut are predominantly full-time positions, a source privy to the development disclosed. Some of the jobs from these centres would be relocated to other technology hubs within the company, although the specifics regarding the number of jobs or their destinations were not provided. This announcement follows last month's report, which indicated that Citigroup was reducing around 200 information technology contractor roles in China. In March, the bank communicated internally its strategy to decrease its reliance on IT contractors and to increase its in-house IT staff, in response to penalties imposed by regulators concerning data governance and control shortcomings. The downsizing in China is part of Citigroup's global restructuring plan, which has also seen the bank scaling back operations in the US, Indonesia, the Philippines, and Poland. The China-based service and technology unit is tasked with delivering financial technology and operations services to support Citigroup's global business operations. Citigroup is currently in the process of establishing a securities unit in China, still maintain the regional presence. Post-reduction, Citigroup's staff count in China is expected to be around 2,000, which includes several hundred employees within the technology division. Citi Japan, Asia North and Australia banking head Marc Luet was quoted by Reuters as saying: "Citi continues to pursue the establishment of a wholly owned securities and futures company in China." "Citigroup to axe around 3,500 tech roles in China " was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store